INS and type 2 diabetes mellitus: It has been observed that the supplement significantly reduced FPG (−88.62 mg/dl, −38.20%, p = .005) compared to the decrease produced by insulin (−144.33 mg/dl, −59.40%, p = .001) in type 1 diabetics and it lowered FPG (−39.50 mg/dl, −25.50%, p = .005) in relation to glibenclamide (−80.62 mg/dl, −44.50%, p = .003) in T2DM patients, after 4 hr.